February 25, 2022 06:03 AM ESTUpdated 09:18 AM

Tillman Gerngross leads a pack of biotech CEOs out the door; With eyes on pipeline expansion, Poseida woos a gene therapy exec from Novartis

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Derek Graf

As market volatility sweeps through the landscape, CEO changes are really ramping up, and topping the list is Tillman Gerngross, a force in the antibody …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Tillman Gerngross leads a pack of biotech CEOs out the door; With eyes on pipeline expansion, Poseida woos a gene therapy exec from Novartis

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Derek Graf

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?

Till­man Gern­gross leads a pack of biotech CEOs out the door; With eyes on pipeline ex­pan­sion, Po­sei­da woos a gene ther­a­py ex­ec from No­var­tis

Copy Chief

Editor

Sign up to read this article for free.

Tillman Gerngross leads a pack of biotech CEOs out the door; With eyes on pipeline expansion, Poseida woos a gene therapy exec from Novartis